NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPass Technologies
September 14, 2026